What is Li-Fraumeni syndrome

Li-Fraumeni syndrome (LFS) is a rare, inherited genetic condition that significantly increases an individual's lifetime risk of developing various types of cancer. It is caused by a germline mutation in the TP53 tumor suppressor gene, which impairs the body's ability to repair damaged DNA and prevent the uncontrolled growth of cells.

What causes Li-Fraumeni syndrome?

The primary cause of Li-Fraumeni syndrome is a pathogenic variant (mutation) in the TP53 gene, located on chromosome 17. In a healthy body, the TP53 gene acts as a "guardian of the genome," producing a protein that stops cells from dividing if their DNA is damaged. When this gene is mutated in Li-Fraumeni syndrome, the protein cannot function correctly, allowing cells with damaged DNA to multiply uncontrollably, which leads to the formation of tumors. While about 70–80% of families with clinical features of LFS have a detectable TP53 mutation, a small percentage may have mutations in other related genes, such as CHEK2, in a condition sometimes referred to as LFS-like syndrome.

Who is affected by Li-Fraumeni syndrome?

Li-Fraumeni syndrome is rare, with an estimated prevalence ranging from 1 in 5,000 to 1 in 20,000 individuals. It affects males and females equally and is found in all ethnic and geographic populations. Because it is an autosomal dominant condition, a person only needs to inherit one mutated copy of the TP53 gene from one parent to be at risk, though approximately 7–20% of cases arise from a de novo (new) mutation in the individual with no family history.

What are the clinical features and cancer risks?

Individuals with Li-Fraumeni syndrome are susceptible to a wide spectrum of malignancies, often at a much younger age than the general population. The disease is characterized by a high penetrance, meaning that those with the mutation are very likely to develop cancer during their lifetime. Common cancers associated with Li-Fraumeni syndrome include:

• Soft-tissue sarcomas (like rhabdomyosarcoma)


• Osteosarcoma (bone cancer)


• Premenopausal breast cancer


• Adrenocortical carcinoma (a rare cancer of the adrenal glands)


• Brain tumors (such as gliomas and choroid plexus carcinomas)


• Leukemias

How is Li-Fraumeni syndrome different from other cancer syndromes?

Unlike hereditary breast and ovarian cancer syndrome (associated with BRCA1/2) or Lynch syndrome, which are linked to specific organ systems, Li-Fraumeni syndrome is distinguished by its remarkably broad "cancer spectrum." The hallmark of LFS is the development of multiple primary cancers throughout a person's life, often occurring in childhood or early adulthood. Currently, 53 people with Li-Fraumeni syndrome have joined the DiseaseMaps.org community to share their experiences and navigate the complexities of managing this high-risk profile.

Next steps

• Consult with a board-certified clinical geneticist to discuss genetic testing options for you and your family.


• Seek a referral to a specialized oncology center that offers high-risk cancer surveillance programs.


• Connect with the 53 members of our community at DiseaseMaps.org to find peer support and shared insights.


• Maintain a proactive screening schedule as recommended by the NCCN (National Comprehensive Cancer Network) guidelines for LFS.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• National Institutes of Health (NIH) - Genetic and Rare Diseases (GARD) Information Center: Li-Fraumeni Syndrome.


• Orphanet: Li-Fraumeni Syndrome (ORPHA:520).


• Online Mendelian Inheritance in Man (OMIM): Li-Fraumeni Syndrome (#151623).


• Li-Fraumeni Syndrome Association (LFSA): Resources for patients and families.